The ELISA-VIDITEST anti-VCA EBV IgG and IgG avidity kit is intended for
in vitro diagnostic procedures in EBV (Epstein-Barr virus)-induced and EBV-associated diseases, such as infectious mononucleosis and the chronic active EBV infection, and for IgG avidity evaluation. The test can be used in the diagnosis of Burkitt’s lymphoma, nasopharyngeal carcinoma, carcinoma of the Waldeyer’s ring and in characterization of opportunistic lymphomas (oligo- and polyclonal). This kit can also be used in characterization of chronic fatigue syndrome, neuro-infection, and immunosuppression that is frequently associated with EBV-reactivation.
This assay is a solid-phase immune-analytical test. The polystyrene strips are coated with specific antigens that bear immunodominant epitopes of VCA (viral capsid antigen) complex. Each serum sample is applied into two parallel wells and the anti-VCA antibodies present in the samples bind to the immobilized antigens. Next, one well is incubated with a wash buffer and the parallel well is incubated with urea solution. The anti-VCA EBV antibodies, if present in the sample, bind to the immobilized antigens and are later recognized by animal anti-human IgG antibodies labeled with horseradish peroxidase. The labeled antibodies are revealed by an enzymatic reaction with a chromogenic substrate. The presence of the low avidity antibodies is indicated by a drop of absorbance in wells to which urea solution was added. The ratio between the optical density of the wells without urea and the corresponding wells with urea represents the relative avidity index.